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It  has  long been  clear  that  there  are  two  components  of the  B  cell  response  to 
antigen.  There  is  an  early  phase  of proliferation  in  which  the  responding  B  cell 
population is expanded many times, and a  later phase of differentiation in which the 
already proliferating B  cell  moves on to the immunoglobulin-secretion  stage.  It has 
been suggested that separate signals are involved in each phase  (1);  it has also been 
realized that  there must be an initial  lag phase  (2)  before the onset of proliferation; 
more recent studies  (3)  have defined this activation step as a  separate event. 
It has been many years since the need for a  helper T  cell in the B cell response to 
antigen  was  defined  (4,  5)  and  since  the  demonstration  that  the  T  cell  could  be 
replaced by a  helper factor (6). 
It  is  now known  that  a  number of T  cell-  and  macrophage-derived  nonantigen- 
specific factors make up the activity previously defined  as  "helper  factor." Current 
studies are underway to characterize each factor and to determine  at which stage it 
acts and what is its exact role.  Parker  (7)  has shown that B cell proliferation  can be 
seen in cultures of positively selected B cells stimulated  with anti-#.  He showed that 
anti-# alone was not sufficient, but that interleukin 2- (IL-2) 1 containing supernatants 
were  also  required.  Immunoglobulin  secretion  required  an  additional  factor  (or 
factors) not provided in IL-2, but which were present in the supernatant of concana- 
valin  A-  (Con A)  stimulated  T  cells.  Howard  et  al.  (8;  and  M.  Howard,  personal 
communication)  also  showed  that  a  number  of factors  were  required  for  B  cell 
proliferation. In her analysis, the extent of proliferation to anti-Ig was proportional to 
the third  power of the B  cell concentration.  The slope of this  curve was reduced  to 
two by the addition  of an IL-2-containing supernatant  from EL4 and to nearly one 
by  the  further  addition  of an  18-mol  wt  cut  from  the  supernatant  of  P388D1 
(presumably, interleukin  1 [IL-1]). The B cell growth factor (BCGF)  activity present 
in the EL4 supernatants could be separated from the IL2 activity by phenyl Sepharose 
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chromatography (8, 9).  A similar activity has been isolated from the supernatants of 
phytohemagglutinin- stimulated human peripheral blood lymphocytes by Kishimoto 
et al. (10). 
In the studies of Howard et al.  (8; and M. Howard, personal communication) this 
combination  of factors did  not  induce  Ig secretion  which  was only seen when  two 
additional  factors were added:  One was an IL-2-containing supernatant  from EL4, 
and the other a T  cell-replacing factor (TRF) containing supernatant from the T  cell 
hybridoma described by Takatsu et al.  (11). 
Very recently, DeFranco et al. (3) have shown that low concentrations of anti-/~ (1 
~tg/ml)  induce blast transformation, but higher concentrations  and/or  other factors 
are required for the cells to enter into the S phase. Other TRF activities and some B 
cell secretion factors have been described (12-17). 
In our own studies  (18-20)  we have shown that antibody-forming cells were only 
obtained  when  both an  IL-2-containing supernatant  and  a  TRF-containing  super- 
natant from the long-term alloreactive Dennert line C.C3.11.75  (DL) were present. In 
this system we measured the IgM response to sheep erythrocytes (SRBC) ofanti-Thy- 
1 and anti-Lyt-2 plus complement-treated Sephadex G-10-passaged B cells from the 
spleens of anti-thymocyte serum- (ATS) injected mice. Similar observations have been 
reported by Leibson et al. (14) using a factor present in Con A-induced supernatants. 
We have called the activity revealed by the IL-2 synergy assay (DL)TRF. 
A  puzzling feature of all these studies  is the apparent  requirement  for the T  cell 
growth factor IL-2. We have found that although some IL-2-containing supernatants 
contained a factor that supported B cell proliferation, this activity did not parallel the 
activity of these supernatants.  However, the TEF  activity of these supernatants,  as 
measured in the antibody response assay, did closely parallel the T  cell growth factor 
activity over a  1000-fold range of activity (19, 20). For this and other reasons we have 
concluded that it is IL2 itself rather than another factor present in the IL-2-containing 
supernatants that is required. 
The DL culture supernatants also have proliferation-inducing activity when assayed 
in the single cell system described by Wetzel and Kettman (2 i) in which the frequency 
of B cell clonal expansion induced by mitogens and other agents can be examined. 
We found that the frequency of B cells induced  to clonal expansion by lipopolysac- 
charide  (LPS)  and  dextran  sulfate under  suboptimum conditions  can be increased 
severalfold by the presence of DL culture  supernatants  (22).  This observation  and 
others  raise  the  question  of whether  these  supernatants  contain  a  single  activity, 
(DL)TRF, active in both assays, or whether a separate factor (or factors) is involved. 
In  the  course  of our  studies,  we  found  that  most  (DL)TRF-containing  culture 
supernatants of the (DL) line contained a  factor that stimulated B cell proliferation. 
We have called this factor (DL)BCGF. In this paper we will present the results on our 
studies of this B cell-growth-promoting activity. We describe here the conditions  for 
the production of large amounts of this activity; its assay, both with normal B cells 
and  the  in  vivo-passaged B  cell  tumor line  BCL1;  and  demonstrate  that  it  can  be 
absorbed  onto  BCL1.  This  B  cell-growth-promoting  activity  can  be  shown  to  be 
distinct  from both IL2 and (DL)TRF. The activity described here is compared with 
the  activities  present  in  a  number  of other  sources  of  B  cell-growth-promoting 
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Materials  and  Methods 
Animals.  Mice of strains  CBA/N,  DBA/2J,  C57BL/6J,  BALB/c, and  BALB/c ByJ were 
raised in our own colony from breeding pairs originally obtained from The Jackson Laboratory, 
Bar Harbor, ME. BALB/c Ke breeding pairs were obtained from the Salk Institute,  La Jolla, 
CA. All Fa hybrid mice were bred in our own colony. 
Monoclonal Antibodies (MoAb).  The cell line making anti-Thy-1.2 F7D5 was a kind gift from 
Dr. Phil Lake  (University College, London  England).  The line making anti-Thy-l.2  H0.13.4 
was  a  kind  gift  of  Dr.  Ann  Marshak-Rothstein  (Massachusetts  Institute  of  Technology, 
Cambridge, MA) and anti-Lyt-2.2 AD4.15 was a kind gift of Dr. Michael Bevan (Scripps Clinic 
and Research Foundation, La Folla, CA). All antibodies were from ascites taken from Pristane- 
injected mice inoculated with tumor cells. 
Tumor Lines.  The in vivo-passaged BCL1 tumor was a kind gift of Dr. Sam Strober' Stanford 
University School of Medicine, Stanford CA. (23). The tumor was maintained by intravenous 
injection of 106 cells from the spleen of tumor-bearing mice 6-10 wk after inoculation. BALB/ 
c  ByJ or BALB/c Ke were used interchangeably  as tumor-bearing animals.  Palpable tumors 
appeared in these mice 4 wk after injection. Tumor cells were used in proliferation experiments 
at anytime between  1 wk after the appearance of tumors  (5 wk) and the death of the animals 
(8-10 wk). BCL1 cells were B cells expressing IgM (24); such cells have previously been shown 
to proliferate and secrete IgM in response to LPS (24) and in responses to anti-Ig and/or certain 
TRF (25)  including (DL)TRF (16). 
Factor-producing Lines.  IL-l-containing supernatants  were obtained by taking the 4- or 5-d 
culture supernatant  of P388D1 cells (26)  originally a  gift of Dr. Steven Mizel. IL-2-containing 
supernatants were obtained from FS6.14.13 (27) or AOFS.21.10.9, gifts of Doctors John Kappler 
and Philippa Marrack (National Jewish Hospital, Denver, CO). The supernatants were induced 
with 2 ~g/ml Con A in the absence of fetal calf serum (FCS). Alpha-methyl mannoside (a mm) 
was  added  to  the  resultant  supernates  at  a  final  concentration  of  10  mM.  (DL)TRF  and 
(DL)BCGF supernatants  were prepared  as  described  previously  (18)  by stimulating  105  DL 
cells/ml  (28)  with  2.5  ×  106, stimulator  eells from  the spleen  of mice bearing  Ia  k that  were 
treated  with  anti-Thy-l.2  plus  complement  and  mitomycin  (25  /~g/ml).  Supernatants  were 
collected after  18-24 h  and stored frozen at -70°C.  In some cases supernatants  were made in 
the absence  of stimulators.  DL cells were cloned  at  0.5  cells per well and  several lines with 
desirable growth and factor production characteristics were chosen. Supernatants were obtained 
from these sublines by similar methods. Supernatant  from the TRF-producing clone B 151K12 
(TAKB15)  (11)  was a  kind gift of Dr. Kiyoshi Takatsu. 
Assay for Normal B  Cell Populations.  (C57BL/6  ×  DBA/2)Fx  (BDF~)  mice  (or, on occasion, 
other strains)  were injected intraperitoneally at 3 and  1 d before killing with 0.06 ml/mouse of 
ATS (Microbiological Associates, Walkersville, MD).  Spleens were removed and treated with 
optimum  doses of two anti-Thy-l.2  MoAb  (F7D5  and  H0.13.4)  and  one anti-Lyt-2.2  MoAb 
(AD4.15)  plus selected guinea pig complement.  Cells depleted of T  cells were then passaged 
through  Sephadex G-10 as described previously (18).  The resulting cells were cultured at 8  × 
106 cells/ml in  microcultures  containing  a  total  vol of 120  ~1.  Factors or other stimuli  were 
added  in  10-20-~1  vol.  Proliferation  of B  cells was  determined  by  adding  0.1  /~Ci  of [I125]  - 
iododeoxy  uridine  ([125I]UdR)  to  cultures  on  day  3.  6  h  later  cultures  were  harvested  and 
washed on a  multiple automatic sample  harvester and  the incorporation  of [x25I]UdR deter- 
mined with a  Searle model 1197 gamma counter (Searle Instruments, Chicago, IL). Geometric 
means  and  SE  of the  counts  per  minute  of triplicate  cultures  were  determined.  Machine 
backgrounds  (30-60 cpm) have been subtracted  from the counts per minute obtained.  Stimu- 
lation  indices  (SI)  were obtained  by  the  ratio  of test  counts  per  minute  divided by  control 
counts per minute. 
BCL1 Proliferation.  Spleens were  removed from  mice bearing  the BCL1  tumor  (recoveries 
varied from 8  X  108-1.3  ×  109 per mouse),  treated  in vitro with two Thy-l.2 MoAb and one 
anti-Lyt-2.2  MoAb as for normal  B  cells. In many cases cells were subsequently  passaged  on 
Sephadex G-10. The resulting cell population was resuspended at 5 ×  105/ml, and 5 ×  104 cells 
were added to microtiter cultures (3596; Costar, Data Packaging, Cambridge, MA). Factors or 
other stimuli were added  in  10- or 20-/LI vol. Proliferation was determined  as described above 
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TRFActivity.  The ability of supernatants to replace T  cells in the antibody-forming response 
was  determined  as  described  previously  (18).  B  cells  prepared  as  above  for  normal  B  cell 
proliferation  were  cultured  at  6  X  105  per well  in  the  presence  of  10-30%  IL-2-containing 
supernatant (FS5.14.13 or AOFS 21.10.9) and 0.01% SRBC. After 4 d ofcuhure, direct plaque- 
forming cells (PFC)  to sheep erythrocytes (SRBC)  were determined by the slide modification 
of the Jerne plaque assay. Geometric means and SE of triplicate cultures were determined. 
IL-2 Activity.  IL-2 activity was measured as reported previously (18) by incubating 5 ×  103 
cells of an IL-2-dependent  NK cell line with several  1:2 dilutions of putative IL-2-containing 
supernatants. [125I]UdR was added at 24 h, and cultures were harvested and the incorporation 
of label was determined as for B cell proliferation. IL-1 activity was determined in a  thymocyte 
costimulator assay, as reported previously (18). 
Results 
Assay  of B  Cell-Growth-promoting Activity from the DL  T  Cell Line.  When cultures of 
the long-term alloreactive T  cell line DL (28) or clones derived from this line (29)  are 
stimulated with IAk-positive T  cell-depleted spleen cells, the 24-h culture supernatants 
contain both an activity that we have called  (DL)TRF, which is necessary for the B 
cell  direct  PFC  response  to  SRBC,  and  a  B  cell-growth-promoting  activity.  Our 
studies with  the  (DL)TRF activity have been previously described  (18).  This study 
concerns the second activity, which promotes B cell proliferation. 
We have assayed this (Fig.  1)  activity in two separate assays by measuring the 6-h 
uptake of [I12S]UdR  by B  cells  after 3  d  of culture  in  the  presence  of DL culture 
supernatants. In the first assay (Fig.  1 A) the B cells are obtained from the anti-Thy- 
1,  anti-Lyt-2  +  complement-treated  Sephadex  G-10  column-passaged  spleen  cells 
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FIG.  1.  Factor activities in B cell  proliferation. Supernatants from T  cell lines were added to T 
cell-depleted B cells  from spleens of normal mice (Materials and Methods) or to T  cell-depleted 
spleens of mice carrying the BCL1 tumor. [12SI]UdR was added for the last 6 h of a  72-h culture. 
O, DL; A, P388D; A, AOFS; O, TAKBIS. SUSAN L.  SWAIN AND RICHARD  W.  DUTTON  1825 
obtained from  mice injected 3  d  and  1 d  before killing with ATS as  described in 
Materials and Methods. In this assay, in contrast to the assay described by Parker (7) 
and by Howard et al. (8), no anti-Ig is added. Significant stimulation is seen when as 
little  as  0.1%  DL  culture  supernatant  is  present,  and  the  inhibition at  higher 
concentrations if often seen. 
In the second assay  (Fig.  1 B),  the  B  cells are  from  the B  cell tumor line BCL1. 
BCLl-enriched populations were obtained from the anti-Thy-1 anti-Lyt-2 spleen cells 
from  mice  inoculated with  BCLx  4-8  wk  before  killing. DL  culture supernatants 
contained B  cell-growth-promoting activity,  as  measured  in  both  assays,  and  the 
degree of stimulation of [12SI]UdR uptake was found to be concentration dependent 
(Fig. 1). Significant stimulation was seen when as little as 0.1% supernatant is present 
in the assay. 
Culture  supernatants  from  other  sources  are  also  active  in  the  normal  B  cell 
proliferation assay (Fig.  1 A). Thus a  modest stimulation is seen with a  supernatant 
from  the  TRF-producing hybridma TAKB15,  the  IL-l-containing supernatant of 
P388D1, and the IL-2-containing  supernatant of AOFS.21.10.9 (hereafter referred to 
as AOFS). 
In the BCL1  proliferation assay  (Fig.  1 B),  only the supernatants from  DL  have 
appreciable activity, with a low level of activity present in the TAKB 15 supernatant. 
P388D1 and AOFS supernatants are negative. The results from a  number of experi- 
ments are summarized in Table I. 
The activities in the AOFS and DL supernatants are additive or slightly synergistic 
in the  normal B  cell assay but  do  not contribute to  BCL1  proliferation (Table II, 
experiment 1). The normal B cell proliferation is enhanced by the presence of anti-/~ 
serum both in the presence or absence of DL supernatants (Table II, experiment 2). 
The BCL1 proliferation was mostly unaffected by the presence of anti-~ serum. The 
TABLE  I 
Summary of Factor Activities in the Proliferation of Normal and BCL1 B Cells 
Additions 
Normal B cells  BCLI B cells 
SI --. SE  N  SI ± SE  N 
IL-1 
IL-2 
TRF 
Other 
P388D1  2.96 (2.17-4.04)  6  0.85 (0.80-0.95)  4 
FS6.14.13  4.16 (3.58-4.83)  15  1.06 (0.89-1.26)  3 
AOFS  2.76 (2.48-3.07)  15  0.96 (0.84-1.09)  4 
DL  2.75 (2.42-3.12)  19  11.26 (9.69-13.08)  13 
TAKBI5  3.77 (3.16-4.49)  12  4.93 (2.81-8.62)  3 
LPS, 5/.tg/ml  14.38 (13.68-15.1 l)  5  23.89 (18.48-30.87)  3 
Results have been pooled from a large number of experiments in which at least three different factors have 
been titrated and proliferation determined. Concentrations of factors from 10 or 15% to 0.01-0.05% have 
been tested in each case. The SI used was the highest one obtained in each titration and the geometric 
means of all the appropriate  SI and their SEM are shown. N, number of separate determinations to 
calculate the mean SI. Normal B ceils were from BDF1, BALB/c, or DBA/2 mice. 1826  B  CELL GROWTH  FACTOR:  PRODUCTION  AND ASSAY 
TABLE  II 
Effect  of Supernatants on Normal B and BCLI Prohferation 
Experi-  Addition  B cell proliferation  BCL1 proliferation  ment 
1  None 
cprn  SI  cprn  SI 
339 (316-362)  1.00  161  (113-224)  1.00 
DL, 0.5*  2,760 (2,580-2,951)  8.14  3,532  (3,25-3,752)  21.94 
DL, 0.1  2,030 (1,950-2,111)  5.99  2,902  (2,805-3,014)  18.02 
DL, 0.02  1,608 (1,235-2,090)  4.74  2,097  (1,852-2,374)  13.02 
AOFS, 10  1,298 (1,217-1,385)  3.83  152 (147-157)  0.94 
AOFS, 1C +DL, 0.5  4,248 (4,119  4,381)  12.53  3,459  (3,141-3,809)  21.48 
AOFS, 10 +DL, 0.1  3,661 (3,327 4,027)  10.80  2,775  (2,489-3,093)  17.24 
AOFS, 10 +DL, 0.02  2,252 (2,224-2,280)  6.64  1,229 (1,072-1,408)  7.63 
2  None  335 (316-356)  1.00  478 (458-499)  1.00 
DL, 1.0  814 (790-838)  2.43  5,993  (5,367 6,692)  12.54 
DL, 0.2  780 (689-881)  2.33  3,739  (3,529-3,952)  7.82 
DL, 0.04  613 (536-700)  1.83  2,316  (2,131-2,517)  4.85 
Anti-/~  932 (925-938)  2.78  454 (453-466)  0.95 
Anti-~ +  DL, 1.0  4,358 (4,286-4,43l)  13.01  2,600 (2,306-2,930)  5.44 
Anti-/L +  DL, 0.2  2,292 (2,076  2,531)  6.84  2,024  (1,875  2,284)  4.23 
Anti-bt +  DL, 0.04  1,237 (1,106 1,384)  3.69  1,418 (1,335  1,506)  2.97 
Results  of two representative experiments in which DL supernatants  mixed with other inducers were 
added to B cell proliferation assays are shown. Results are presented as both geometric mean counts per 
minute per culture (_+SE) and as SI. A machine background of 50 cpm has been subtracted from  all 
counts. 
* Percentage (vol/vol), 
apparent  depression  seen when  anti-bt  was  added  to the highest  concentration  of DL 
supernatant  was seen  in some,  but  not  all, experiments.  Thus  there are a  number  of 
differences in the characteristics  of the two assays. 
The amount  of B  cell-growth-promoting activity in a  variety of DL supernatants  is 
not  proportional  to the amount  of (DL)TRF  measured  in  the IL-2 synergy  assay  (S. 
L.  Swain,  unpubished  results)  and  is therefore most  likely the property  of a  different 
factor.  More definitive evidence for this was provided by the absorption  experiments 
shown  below. 
Absorption of B  Cell-Growth-promoting Activity on BCLI  Cells.  DL culture supernatants 
with  high  levels  of  B  cell-growth-promoting  activity  were  absorbed  with  in  vivo 
passaged  BCI1  as  described  in  Materials  and  Methods.  The  resulting  absorbed 
supernatants  were assayed  for residual  growth-promoting  activity in  the  two  B  cell- 
proliferation assays  and  for  (DL)TRF  activity in the  PFC  synergy assay.  The  results 
are shown in Fig. 2. It can be seen that the B  cell-growth-promoting activity absorbed 
on BCL1, as measured  in both the normal B  (Fig. 2 A) and BCL1  (Fig. 2 B) assay, but 
there  was only a  slight  reduction  in  the  (DL)TRF  activity as  assayed  in  the synergy 
assay (Fig. 2 C). The presence of the absorbed  supernatant  did not inhibit the activity 
in the unabsorbed  supernatant  (legend to Fig.  2). 1827 
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F1o.  2.  Effect of BCL1  absorption on DL activities.  1-ml aliquots of DL supernatant were either 
incubated without cells (control, O) or with a total of 4 ×  10  s BCL1 cells (absorbed BCLI, 0). The 
absorption was done for 2 h at room temperature on 2 X  l0  s cells followed by absorptions on  l0  s 
cells each. Both supernatants were then dialyzed before testing. The same supernatants were tested 
for activity in the three assays shown. When a 50:50 mix of absorbed and control supernatants was 
tested at 2% in the BCL1  proliferation assay the proliferation was 89% of the control alone. Mixes 
at other concentrations also showed no evidence of suppression. 
The BCLl-containing spleens were still  able to absorb the activity when treated 
with anti-Thy-l.2 and  complement or after glutaraldehyde fixation  (Fig.  3).  Com- 
parable  numbers  of normal  BALB/c  spleen  cells  did  not  produce  a  measurable 
reduction  in  B  cell-growth-promoting  activity  (Fig.  4).  None  of these  absorption 
significantly affected the TRF activity of the supernatants (Table III). 
Enhanced Production of B  Cell-Growth-promoting  Activity from DL.  The level of B cell- 
growth-promoting  activity  in  the  supernatants  of IAk-stimulated  DL  cultures  is 
somewhat variable. It can be markedly enhanced, however, when DL is cultured in 
the presence of IL-2-containing supernatants (Fig. 5). In these experiments there is no 
need to add IAk-positive stimulator  cells, and  the IL-2-containing  culture  supernatants 
used  to  induce  the  production  contained  negligible  amounts  of B  cell-promoting 
activity when assayed directly. It is clear that  the B cell-growth-promoting activity 
must  come  from  the  DL  cells  themselves  and  is  therefore a  T  cell  product.  The 
increased production of B cell-growth-promoting activity, caused by stimulation with 
IL-2-containing supernatant is, in general, accompanied by a reduction in the output 
of (DL)TRF activity. 
Production of B  Cell-Growth-promoting Activity from  T  Cell  Clones Obtained from  the DL 
Line.  A number of clones or sublines have been obtained in our laboratory from DL 
cells. The clones were obtained by cloning at 0.5 cells per well. Some of these clones 
(Table  IV,  DL.A4  DL.B10)  were  able  to  produce  large  amounts  of B  cell-growth- 
promoting  activity  when  cultured  under  the  appropriate  conditions.  One  of  these 
clones DL.A4 (Table IV) produced appreciable levels of (DL)TRF and B cell-growth- 
promoting  activity  constitutively  in  the  absence  of stimulators  of IL2-containing 
supernatants.  It should  be noted  that  these clones are still antigen  reactive and  require 1828  B CELL GROWTH FACTOR:  PRODUCTION  AND ASSAY 
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FIG. 3.  Absorption  of DL on BCL1 cells. 1-ml aliquots of DL supernatant were either incubated 
without cells (DL control, C)), or with  1% glutaraldehyde-fixed spleen cells from BCL-carrying 
mice that were treated in vitro with two anti-Thy-l.2 MoAb plus complement (0), or with T cell- 
depleted BCL1 cells (A). Absorptions  were done as in Fig. 2. Supernatants were added to normal or 
BCLz B cells as described in Fig. 2. The TRF activity of these supernatants is shown in Table III. 
50:50 mix of control and absorbed supernatants added at -<2% gave BCL1 proliferation within 20% 
of that with control supernatant alone. 
antigen stimulation for their propagation. 
B  Cells from  X-linked Deficient  (CBA/N  X  DBA/2)F1  Mice.  B  cells  from  female 
(normal) or male (deficient) F1 mice were cultured with a  variety of culture super- 
natants containing B cell-growth-promoting activity (Table V). It can be seen that B 
cells  from  the  deficient  mice  showed  little  or  no  response  to  these  supernatants 
compared with those from the normal mice. 
Discussion 
B  Cell Growth-promoting Activity  and Its Assay.  The results presented here show that 
there is a  B cell-growth-promoting activity present in the culture supernatants of the 
DL cell line. This activity can be scored in two B  cell assays. In one, the B cells are 
obtained from the spleens of normal mice; in the other, the B cells are obtained from 
mice carrying the in vivo B cell tumor line BCL1. The spleens from which the latter 
B cell preparation is made contain from 70 to 90% tumor cells. In both preparations, 
exhaustive efforts were made to remove non-B cells. The spleen cell suspensions were 
treated  with  anti-Thy-1 and anti-Lyt-2 MoAB  and complement and were  usually 
passaged through Sephadex G-10 columns. In the case of the normal B cell prepara- 
tions the mice were injected with ATS before killing. 
Our goal in developing a  B cell-proliferation assay is to provide a  system in which 
the  responding B  cell is acted  on directly by only a  single factor  and responds by 
proliferation.  There  are  a  number of indications, however,  that  suggest  that  the SUSAN L.  SWAIN  AND  RICHARD  W.  DUTTON  1829 
20,000 - 
ud  10,000 -  Og 
I,- 
-J  5000 
U 
O.  2000 
Q. 
U  1000 
500- 
NORMAL  B  CELLS  BCL  1  CELLS 
--,--/  ~  ---~ t-,----r----,----r~ 
0  0.12  0.6  3  15  0  0.4  0.120.6  3  15 
%  SUPERNATAHT 
Fro.  4.  Absorption of DL on normal and BCL cells. Aliquots of DL supernatant were absorbed 
with no cells (O), or with T cell-depleted BCLx (O) or BALB/c (&) spleen cells as described in the 
legend to Fig. 2. Supernatants were tested for their effect on proliferation on normal B cells and 
BCLa cells. The TRF activity of supernatants absorbed in an identical manner is shown in Table 
III. 
TABLE  III 
Effect of Absorption  of DL Supernatants  on Their TRF Activity 
Experi-  Cells for absorption 
ment 
PFC per culture +  SE 
5%*  1%*  0.2%* 
None  305 (270-344)  127 (82-97)  51  (15-176) 
T-depleted BCL~  481  (361-641)  346 (302-396)  86 (73-101) 
Glutaraldehyde-fixed BCL1  209 (158-275)  151  (118-193)  101  (62-163) 
None  132 (110-185)  109 (106-113)  82 (63-107) 
BGL1  352 (154-804)  124 (104-148)  49 (34-72) 
BALB/c  65 (44-96)  181  (151-210)  7 (5-12) 
In experiment l the same supernatants shown in Fig. 3 were tested for TRF activity in synergy with IL2. 
In experiment 2 supernatants were prepared in an identical manner to those shown in Fig. 4 and were 
tested. PFC to SRBC were determined on day 4. The background PFC in cultures without TRF were 28 
(24-32). The geometric means (±SE) of triplicate cultures is shown. 
* Percent (vol/vol)  of DL supernatants. 
normal B  cell assay and perhaps the BCL1 assay are still complex. 
First, it  is clear that the two assays do not have the same response characteristics. 
The BCLa assay responds only to the DL line culture supernatants and those from the 
TRF-containing  supernatants  of the  Takatsu  hybridoma  TAKB15.  The  normal  B 
cell assay responds, in addition, to an IL-l-containing  supernatant  from cultures of 1830  B  CELL GROWTH  FACTOR:  PRODUCTION  AND ASSAY 
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Fro.  5.  IL-2  induces  B cell proliferation factor(s).  Aliquots of a  pool of DL cells at  10  °~in 1-ml 
Linbro cultures were incubated either with stimulators (2.5 ×  106 spleen cells from BALB.K, which 
had  been  treated  with  anti-Thy-l.2  MoAb  and  complement,  and  mitomycin)  or with  varying 
concentration of supernatants from AOFS (a source of IL-2). These supernatants were subsequently 
tested  in the four assays shown. 
TABLE  IV 
Induction of B  Cell Proliferation Activity 
Cells  Inducer  BeLl proliferation 
cpm  SI 
None  AOFS (IL2)  119 (110-129)  1.0 
DL-9  None  495 (447-547)  4.2 
AOFS (IL2)  1,497 (1,487  1,507)  12.6 
DL.A4  None  1,032 (1,00%1,056)  8.7 
AOFS (IL2)  1,812 (1,785  1,891)  15.2 
DL.B10  None  483 (411  545)  4.1 
AOFS (IL2)  1,433 (1,302-1,576)  12.0 
Cells of the original DL line (DL.9) and two subclones  were incubated either 
alone or with 30% AOFS. Supernatants  were collected after 24 h and tested 
for B cell growth-promotion activity. 
P388D1  and  to an IL-2-containing supernatant,  AOFS. 
The  normal  B  cell assay  shows  additive  effects when  combinations  of stimulators 
are  present.  The  BCL1  assay  responding  only to  the  activity in  the  DL  or TAKB15 
supernatants  is  not  affected  by  additional  factors.  We  speculate  that  although  the 
BCL1  B  cell preparation  contains predominantly  the tumor BCL1 cell at a  particular 
stage of differentiation, the normal B  cell population  may contain a  variety of subsets 
or populations  of B  cells at  different  stages of differentiation.  It  is also  possible  that 
there  are  more  contaminating,  non-B  cells present  in  the  normal  B  cell  population 
that  can act as intermediaries  in the response  to a  variety of factors. 
The  BCLa  assay  is clearly  less  complex.  It  is of interest  that,  in  contrast  to  other 
assays  (3,  7, 8, 30)  the BCL1 assay does not require the presence of the agent  anti-/1 to 
provide a  polyclonal  activator  signal,  nor does  it  require  the  presence  of added  IL-1 SUSAN L.  SWAIN AND RICHARD W.  DUTTON  1831 
TABLE  V 
X-h'nked Defect in B Cell Proliferation 
Experi-  Addition  (CBA/N × DBA/2)F1 ~  (CBA/N × DBA/2)F1 d'  ment 
cpm/  culture  SI  cpm  / culture  SI 
None  250 (244-257)  1.00  39  (31-46)  !.00 
AOFS, 15%*  483 (425-526)  1.93  80  (69-93)  2.05 
DL, 2%  529 (491-570)  2.12  40  (26-57)  1.03 
LPS, 1/~g/ml  3,198 (2,935-3,483)  12.79  235  (206-266)  6.03 
Anti-Ig, 50 #g/ml  9,124 (8,761-9,502)  36.50  348  (285-424)  8.92 
2  None  294 (278-310)  1.00  23  (16-30)  1.00 
FS6, 15.0%  1,643 (1,476-1,828)  5.59  20  (12-28)  0.87 
FS6, 3.8%  1,246 (1,186-1,310)  4.24  42  (34-51)  1.83 
FS6, 1.0%  834 (819-848)  2.84  12  (5-20)  0.52 
DL, I5.0%  1,415 (1,344-1,490)  4.81  20  (16-25)  0.87 
DL, 3.0%  1,129 (1,087-1,183)  3.84  28  (22-34)  1.22 
DL, 1.0%  881 (836-928)  3.00  22  (18-26)  0.96 
DL, 0.2%  624 (593-659)  2.12  16  (6-25)  0.70 
LPS, 10 #g/ml  9,550 (9,111-10,010)  32.48  2,012 (1,812-2,253)  87.48 
LPS, 2 #g/ml  8,348 (8,054-8,651)  28.39  123  (91-163)  5.35 
Two representative experiments are shown in which the spleen cells of (CBA/N X DBA/2)F1 female and 
male littermates were compared for their proliferation  in response to supernatants  and other inducers. 
Results are presented both as geometric mean (counts per minute) per culture (±SE) and SI. 
* Vol/vol. 
or IL-2 (because these are absent from the DL supernatants). 
Although the BCL1 assay may at first appear to fulfill the criteria of an ideal assay, 
as exemplified by the  IL-2 assay that  uses a  T  cell growth  factor-dependent T  cell 
line, we  do  not  believe that  the  two  assays are  necessarily comparable.  The  BCL1 
preparation  is  not  a  cloned  line  and  experiments  in  which  we  have  titrated  the 
proliferation  response  against  B  cell  number  (now  in  progress)  at  least  raise  the 
possibility that other cells may still be involved. For this, and other reasons, we have 
referred to the activity as B cell growth-promoting factor rather than a  growth factor 
per se. We have, however, used the abbreviation BCGF, because this is the abbrevi- 
ation  used  by  other  groups  (8,  10)  to  designate  a  similar  activity.  It  should  be 
emphasized,  however,  that  the  BCL1  assay in  its present  form  does provide  a  very 
sensitive and  selective assay for  the  B  cell-growth-promoting activity and  does not 
respond to IL-1, IL-2, or (DL)TRF  (see below). 
(DL)BCGF Can Be Distinguished from  (DL)TRF, IL-2, and IL-1.  The DL superna- 
tants contain an activity, (DL)TRF, that we have measured in the IL2 synergy assay 
(18)  in  which  the  B  cell response  to  SRBC  is scored.  Most  preparations  with  high 
(DL)BCGF  activity are  devoid of measurable  ILl  or  IL2  activity. The  (DL)BCGF 
activity can be reduced at least  100-fold by absorption to BCL1 tumor cells, whereas 
the  (DL)TRF activity is reduced no more than  the degree expected by the dilution 
inherent  in  the absorption  procedure.  The  (DL)BCGF  and  (DL)TRF  activities are 
clearly separated by this procedure. That  the apparent  absorption is not  a  result of 
the release of an inhibitor material is shown by the appropriate mix experiments (see 1832  B CELL GROWTH FACTOR: PRODUCTION AND ASSAY 
legend  to  Fig.  2).  Glutaraldehyde-fixed  BCL1  preparations  also  offer  compelling 
evidence that the effect is indeed a  result of a passive process of absorption and does 
not appear to require any metabolic event. Anti-Thy- 1 and complement-treated BCL1 
preparations from ATS-pretreated mice are also effective, whereas comparable num- 
bers of normal BALB/c T  cell-depleted spleen cells  show no measurable removal of 
activity. One might have imagined that normal spleen would contain some cells with 
receptors for the activity; the explanation  for the striking difference between  BCL1 
and normal spleen is not immediately apparent. 
The Production of (DL)BCGF.  The DL line  is  maintained  by weekly stimulation 
with  IAk-positive stimulator cells.  In our previous studies  (18) we have,  in  general, 
harvested  culture  supernatants  24  h  after  antigenic  restimulation.  Such  culture 
supernatants contain somewhat variable amounts of (DL)TRF and, as described here, 
(DL)BCGF. We have adopted two strategies to increase the level of these activities, to 
produce supernatants with predominantly one activity or the other, and to demon- 
strate that the activities are the product of the T  cell line and do not come from the 
stimulator cells. 
In the first  method we have shown that large amounts of (DL)BCGF activity can 
be  obtained  if DL  is  cultured  in  IL-2-containing supernatants  instead  of the  IA  k- 
positive stimulator cells  1 wk after the last  stimulation.  This induction of increased 
factor production is reminiscent of the effect described by Raulet et al.  (31) in which 
increased levels of TRF activity were obtained from cells cultured with IL-2. 
In the second, we have derived clones or sublines  of the original  line.  Several of 
these  sublines,  e.g.,  DL.B10,  can  be  induced  to  produce high  levels  of (DL)BCGF 
activity  on  culture  with  IL-2-containing  supernatants,  whereas  another,  DL.A4, 
produces a  substantial  level  of (DL)BCGF in the absence of IA  k or IL2 stimulation. 
These  observations provide direct  evidence that  the  (DL)BCGF activity is  derived 
from the T  cell line itself and provide an excellent source of material for purification 
and other studies. 
Lack of Reactivity of B Cells  from the Spleens of X-linked Deficient Mice.  B cell prepara- 
tions from the spleens of (DBA/2 ×  CBA/N)F1 male mice were prepared in the same 
way as described for the B cells  for the normal B cell assay. These cells  show little or 
no response to the (DL)BCGF preparations or other preparations that stimulated the 
B  cells  from  normal  (DBA/2  ×  CBA/N)F1  female  littermates.  This  observation  is 
compatible with the findings of a number of other investigators (32, 33). 
One interpretation  of this observation would be that the  (DL)BCGF acts only on 
the subset of B cells  that is missing in the X-linked deficient mice. The nature of the 
X-linked defect is still unclear, however, and other interpretations cannot be excluded 
yet. It is possible, for example, that in the deficient mouse B cells of both subsets fail 
to  reach  the  differentiation  state  in  which  they  can  respond  to  the  (DL)BCGF, 
whereas in normal mice both can respond. 
Summary 
Culture supernatants  from a  long-term alloreactive T  cell  line,  the  Dennert  line 
C.C3.11.75  (DL)  contain  a  B  cell-growth-promoting activity.  This  activity can  be 
assayed on normal B cells  or on the  in  vivo BCL1  tumor line.  We have called  this 
activity  (DL)BCGF.  This  activity  can  be  distinguished  from  the  T  cell-replacing 
factor activity we had earlier found in DL supernates  [(DL)TRF], which is required SUSAN  L.  SWAIN AND RICHARD W.  DUTTON  1833 
together with IL2 for the B cell plaque-forming cell response to erythrocyte antigens. 
The  (DL)BCGF  can  be absorbed on  untreated  or glutaraldehyde-fixed BCLa.  This 
absorption  does  not  remove  (DL)TRF  activity.  The  production  of  (DL)BCGF  is 
greatly enhanced when DL is cultured with IL2-containing supernatants. Sublines or 
clones of DL  (DL.B10 and DL.A4)  have been obtained that make large amounts of 
(DL)BCGF in the absence of any stimulator cells or IL2. B cells from the xia-deficient 
male (DBA/2 ×  CBA/N)Fx mice do not respond to (DL)BCGF. 
We thank Dr. Sam Strober for donating the BCLx line, and Dr. Gunther Dennert for donating 
the original C.C3.11.75  (DL) line. We thank Michele English and Linda Walker for technical 
assistance, Kathy Wong for secretarial assistance, and Dr. Monte Wetzel for useful discussion. 
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